The World In A Grain Of Sand

The World in a Grain of Sand: BioAge

Listen Later

KdT Ventures presents The World in a Grain of Sand, where we break down an S1 from a recent biotech IPO and share insights on the science, business models, and financials. In this episode, Cain McClary and Phil Grayeski discuss BioAge, a longevity biotech with a pipeline of therapies for diseases of aging including cardiometabolic disease and neuroinflammation. Please note that this episode was recorded before the clinical readout of BioAge's apelin receptor agonist Azelaprag.

We dive into:

  • BioAge's founding by first-time biotech entrepreneur Kristen Fortnoy as a Stanford spinout analyzing aging-related biomarkers
  • Their pivot from platform to asset in-licensing, securing Azelaprog from Amgen after discovering its potential in obesity when combined with GLP-1 drugs
  • Their clinical strategy running combination trials with both Lilly's Zepbound and Novo's Wegovy, supported by a strategic supply agreement giving Lilly first negotiation rights
  • A dramatic survival story of navigating near-death in 2022-2023 through bridge financing


    • ...more
    View all episodesView all episodes
    Download on the App Store
    The World In A Grain Of SandBy KdT Ventures
    • 5
    • 5
    • 5
    • 5
    • 5

    5

    19 ratings

    More shows like The World In A Grain Of Sand

    View all
    The Bill Simmons Podcast by The Ringer

    The Bill Simmons Podcast

    30,014 Listeners

    The Long Run with Luke Timmerman by Timmerman Report

    The Long Run with Luke Timmerman

    117 Listeners

    Business Of Biotech by Matt Pillar

    Business Of Biotech

    84 Listeners